Skip to main content

RETRACTION article

Front. Oncol., 06 August 2024
Sec. Cancer Genetics
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1469700

Retraction: MiR-1236-3p inhibits the proliferation, invasion, and migration of colon cancer cells and hinders epithelial-mesenchymal transition by targeting DCLK3

This article is a retraction of:

  1. RETRACTED: MiR-1236-3p Inhibits the Proliferation, Invasion, and Migration of Colon Cancer Cells and Hinders Epithelial-Mesenchymal Transition by Targeting DCLK3

    1. Read original article
Frontiers Editorial Office* Frontiers Editorial Office*

    A Retraction of the Original Research Article
    MiR-1236-3p inhibits the proliferation, invasion, and migration of colon cancer cells and hinders epithelial-mesenchymal transition by targeting DCLK3

    By Zhao Y, Zhou H, Shen J, Yang S, Deng K, Li Q and Cui W (2021) Front. Oncol. 11:688882. doi: 10.3389/fonc.2021.688882

    The journal retracts the September 3rd 2021 article cited above.

    Following publication, concerns were raised regarding the integrity of the images in the published figures. Images presented in this article were subsequently also identified in publications from unrelated author groups. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

    This retraction was approved by the Chief Executive Editor of Frontiers. The authors received a communication regarding the retraction and agree to retract the article. This communication has been recorded by the publisher.

    Frontiers would like to thank Dr Sholto David for contacting the journal regarding the published article, the concerns regarding which were also documented on PubPeer.

    Citation: Frontiers Editorial Office (2024) Retraction: MiR-1236-3p inhibits the proliferation, invasion, and migration of colon cancer cells and hinders epithelial-mesenchymal transition by targeting DCLK3. Front. Oncol. 14:1469700. doi: 10.3389/fonc.2024.1469700

    Received: 24 July 2024; Accepted: 24 July 2024;
    Published: 06 August 2024.

    Approved by:

    Frontiers Editorial Office, Frontiers Media SA, Switzerland

    Copyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    *Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.